Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
Clover Biopharmaceuticals, Ltd. held a successful Annual General Meeting on June 20, 2024, where all resolutions proposed were overwhelmingly passed with nearly unanimous support. Key approvals included the adoption of audited financials, re-election of directors, and authorization for share dealings and auditor remuneration. The meeting also resulted in the adoption of new amendments to the company’s memorandum and articles of association.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.
